Bio Protocol

BIO Protocol

2026-09-26 09:00:07

BIO Protocol to unlock about 30.8 million BIO tokens on Oct. 3

BIO Protocol (BIO) is scheduled to unlock about 30.8 million tokens at 10:00 Beijing time on Oct. 3, according to token unlock data from Web3 asset data platform RootData. The unlocked tranche is valued at about $1 million based on the figures cited in the report. The update was published by ChainCatcher as a brief market data item. The source material did not provide additional details on the allocation, circulating supply impact, or recipient categories tied to the unlock. No further timeline changes or related token release information were included in the original report.

1790

Bio Protocol

2026-09-15 16:38:01

Bio Protocol to launch NeuroLab AI NDT Ignition Sale on Sept. 16

Bio Protocol said NeuroLab AI, a project built by NootropicsDAO, will begin its Ignition Sale on the Bio Protocol platform at 14:00 UTC on Sept. 16, with NDT as the token being offered. The sale will run for two weeks. Participation requires staking USDC, with users also able to pair their position with BioXP. According to Bio Protocol, NeuroLab AI is designed to predict the potential effects of compounds on the brain and link molecular interactions with cognitive-equivalent effects, with the stated goal of helping researchers decide which candidates should move to the next round of lab testing. The project said its knowledge graph has organized more than 150,000 entries and over 8 million relationships. The initial raise is set at $200,000, with a starting fully diluted valuation of $3 million and initial project funding of $100,000. Bio Protocol added that participant allocations will be 100% unlocked at claim, with no lock-up and no linear vesting. veBIO holders will receive a 20% allocation and can claim at any time, though any unvested portion is forfeited upon claiming. Of that allocation, 20% is unlocked at TGE and the remainder will vest linearly over six months. The Ignition Sale allocation is 6.67%.

1630

Bio Protocol

2026-07-24 07:40:18

Bio Protocol Launches OpenLabs to Combine AI Collaboration With USDC Yield Funding

Bio Protocol has launched OpenLabs, a DeSci platform that lets researchers post hypotheses, receive community votes, work with AI agents, and tap USDC yield-based funding for scientific projects.

940

BIO

2026-07-10 21:26:13

Bio Protocol Transfers 80M BIO Tokens to Binance and OKX, Price Doubles in Two Days

On May 2, 2026, Bio Protocol moved 80 million BIO tokens (~$5.15M) to Binance and OKX following a new staking event. BIO price surged 100% in two days, drawing significant market attention.

990

Bio Protocol

2026-07-10 08:26:13

Bio Protocol Launches PEPTAI Token on Base Chain, AI-Driven Peptide Drug Discovery Fuels DeSci Boom

Bio Protocol officially launched the PEPTAI token on Base Chain, integrating an AI agent for peptide drug discovery. 20% of supply is allocated to BIO stakers. The token's market cap briefly exceeded $15 million within 5 minutes, stabilizing at $13.5 million with $2.2 million trading volume.

820

DeSci

2026-07-08 12:18:15

Rise of DeSci Tokens: Top 10 Decentralized Science Tokens to Invest in 2025

DeSci uses blockchain to transform scientific research with transparency, collaboration, and open access. This article explores DeSci token utilities and ranks the top 10 tokens for 2025, including BIO, TRAC, RSC, VITA, and more.

2100

BIO Protocol

2026-07-08 10:00:12

BIO Protocol Explained: DeSci Biotech Funding, BioDAOs, and Tokenomics in Focus

BIO Protocol aims to bring decentralized science to biotech funding through BioDAOs, tokenized IP, and community governance. Here is a closer look at its model, milestones, token utility, and market relevance.

780

BIO Protocol

2026-07-08 09:58:12

BIO Protocol in Focus: DeSci Ambitions, Token Utility, and Market Signals

BIO Protocol is positioning itself at the intersection of crypto, biotech, and decentralized science. This article reviews its BioDAO model, BIO token utility, tokenomics, project milestones, and the broader market implications for the DeSci sector.

890